Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | DREAMM-6: Belamaf with BorDex for R/R myeloma

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares the preliminary results of the Phase I DREAMM-6 trial (NCT03544281) evaluating the safety and efficacy of belantamab mefodotin (belamaf) in combination with bortezomib and dexamethasone (BorDex) in patients with relapsed/refractory (R/R) multiple myeloma. The interim data shows the combination is well tolerated with no new safety signals or dose-limiting toxicities. Patients have displayed a significant overall response rate of 78%, supporting the continued investigation of the combination in Phase III trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Honoraria: Takeda, Abbvie, GSK
Consultancy: BMS, Janssen, GSK